Oral GLP‑1 pills hit the market

Weight-loss drugs that were mostly shots now come in pills, after the Food and Drug Administration approved Eli Lilly’s Foundayo on April 1 and cleared Novo Nordisk’s Wegovy tablet in December. (fda.gov, accessdata.fda.gov) Foundayo is orforglipron, a once-daily tablet for adults with obesity or adults who are overweight and have at least one weight-related condition. The Food and Drug Administration said patients should use it with a reduced-calorie diet and more physical activity. (fda.gov) The agency approved Foundayo 50 days after filing under its Commissioner’s National Priority Voucher pilot, 294 days ahead of the original January 20, 2027 target date. The Food and Drug Administration called it the fastest approval of a new molecular entity since 2002. (fda.gov) These medicines copy the effect of a gut hormone called glucagon-like peptide-1, which helps people feel full and eat less. Until recently, the weight-loss versions were mostly weekly injections such as Wegovy and Zepbound. (fda.gov, accessdata.fda.gov) Novo Nordisk’s Wegovy tablet, approved on December 22, 2025, is a once-daily 25 milligram oral semaglutide pill. Its label covers long-term weight reduction and cutting the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. (accessdata.fda.gov, kommunikasjon.ntb.no) Lilly is pitching a different convenience point. The Food and Drug Administration said Foundayo is taken once a day by mouth, and Lilly said it does not need empty-stomach timing or food-and-water restrictions. (fda.gov, prnewswire.com) The trial numbers are close enough to fuel a direct rivalry. Novo Nordisk said adults in the OASIS 4 trial lost 16.6% of body weight on average when treatment was adhered to, while Lilly said adults on the highest Foundayo dose lost an average of 27 pounds in ATTAIN-1, about 12.4% of body weight. (kommunikasjon.ntb.no, prnewswire.com) Distribution is shifting with the format. Lilly said prescriptions for Foundayo were accepted immediately through LillyDirect, with shipping starting April 6, and Amazon Pharmacy said in February that it plans same-day prescription delivery in nearly 4,500 United States cities and towns by the end of 2026. (prnewswire.com, aboutamazon.com) Amazon says the expansion is aimed at places hit by pharmacy closures, staffing shortages, and long drives to pick up medicine. In communities on the Navajo Nation, Amazon said the nearest brick-and-mortar pharmacy can be 45 to 60 minutes away and other mail-order services can take five to 10 days. (aboutamazon.com) Oral glucagon-like peptide-1 drugs are not entirely new: the Food and Drug Administration approved Rybelsus, an oral semaglutide pill for type 2 diabetes, in 2019. What changed in 2025 and 2026 is that higher-dose pills for obesity reached the market, giving drugmakers a tablet option in a business built on injections. (fda.gov, accessdata.fda.gov, fda.gov) The next test is not whether the pills work; regulators have answered that. The next test is whether patients, insurers, pharmacies, and delivery networks treat a daily tablet as easier to start and easier to keep taking than a weekly shot. (fda.gov, aboutamazon.com, kommunikasjon.ntb.no)